MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

1.580 +0.020 (+1.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a... 
Via Newsfile
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise ↗
The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 
Via Stocktwits
News headline image
Crude Oil Down 2%; D.R. Horton Earnings Top Views ↗
 
Via Benzinga
News headline image
Why InMed Pharmaceuticals (INM) Stock Is Skyrocketing ↗
InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study. 
Via Benzinga
News headline image
Dow Jumps 200 Points; 3M Posts Upbeat Q4 Results ↗
 
Via Benzinga
Topics Stocks
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Fiscal 2024 Financial Results, Provides Business Update
Via Investor Brand Network
Topics Intellectual Property
CBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) BayMedica Poised as Rare Cannabinoids Drive Market Growth
Via Investor Brand Network
Topics Cannabis
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901
Via Investor Brand Network
News headline image
Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Crude Oil Falls; Palo Alto Networks Shares Jump After Q4 Earnings ↗
 
Via Benzinga
News headline image
Nasdaq Moves Lower; Medtronic Posts Upbeat Earnings ↗
 
Via Benzinga
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment
Via Investor Brand Network
News headline image
InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday ↗
InMed Pharmaceuticals advances INM-901 as an oral treatment for Alzheimer's. Preclinical studies show the small molecule drug achieves effective brain levels, offering a promising alternative to... 
Via Benzinga
News headline image
US Stocks Mixed; Lowe's Cuts FY24 Forecast ↗
 
Via Benzinga
BioMedNewsBreaks — InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD
Via Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via CannabisNewsWire
Topics Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”
Via Investor Brand Network
Topics Cannabis
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via Investor Brand Network
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Via CannabisNewsWire
News headline image
The Rising Importance Of Minor Cannabinoids In The Growing Edible Market
The Rising Importance Of Minor Cannabinoids In The Growing Edible Market 
Via News Direct
Topics Cannabis
BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Significant Improvements from INM-089 in AMD, Validates INM-901 as Potential AD Treatment
Via Investor Brand Network
News headline image
7 F-Rated Growth Stocks to Avoid Right Now: June 2024 ↗
A good rating for growth in the Portfolio Grader doesn't tell the full picture. These are all growth stocks to avoid now. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story